dates glp 1 What to Make of the GLP-1 Coverage and Cost Landscape Beyond glycemia: Comparing tirzepatide to

Oral lesions presented each as an asymptomatic pigmented dark-brown macule with an intact mucosal surface and well-defined borders, except case 2

Hegele b Purpose of review Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are becoming more prominent as a therapeutic choice in diabetes management and their use is being expanded to other indications, such as obesity

(6) cardiovascular event during the last 6 months

Best candidates for retatrutide Retatrutide makes more sense for researchers who: Need maximum possible weight loss and have not achieved adequate results with dual agonists Have significant liver fat accumulation as a primary concern Have plateaued on tirzepatide or stopped responding Are comfortable with investigational compounds and research-grade sourcing Have higher side effect tolerance Want the most comprehensive metabolic intervention currently available Are experienced with GLP-1 agonist protocols and understand escalation management Have access to medical monitoring during the protocol Retatrutide is not a beginner compound

doi:10.1007/s12070-019-01655-5